Biotechnology

Qiming's Portfolio Company Rendu Biotechnology Lists on STAR Market

SHANGHAI, March 30, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company Rendu Biotechnology (SESH: 688193), a leader in RNA molecular diagnostics inChina, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is...

2022-03-30 10:22 2313

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's robust SINE programs. SHANGHAI and HONG KONG, March 30, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutic...

2022-03-30 09:00 1840

RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

GAITHERSBURG, Md., March 30, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company " or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximatelyUS$27 million Series A round of fina...

2022-03-30 08:31 1887

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2022-03-30 08:05 2436

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong Pharmaceutical expects to strengthen its global business in key markets of ASEAN countries by obtaining marketing authorization in foreign countries with its branch offices SEOUL, South Korea, Marc...

2022-03-29 09:00 2022

ILC Dover Announces Liquid Single-Use Bioprocessing Bags for Rapidly Growing Biotherapeutics and Cell & Gene Therapy Markets

NEWARK, Del., March 29, 2022 /PRNewswire/ -- ILC Dover LP ("ILC Dover" or the "Company"), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced its launch of liquid single-use bioprocessing bags, representing the first of many new products fo...

2022-03-29 05:11 1229

Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%

Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...

2022-03-29 01:01 2364

Vela Diagnostics Launches Focused (60 Genes) and Comprehensive (525 Genes) NGS-Based Pan-Cancer Panels

HAMBURG, Germany, March 28, 2022 /PRNewswire/ -- Vela Diagnostics announced today the launch of its new OncoKey® SL 60 and 525 Plus Panels. These next-generation sequencing (NGS)-based panels are intended for detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) ...

2022-03-28 15:00 1322

Innovent and Lilly Expand Strategic Partnership in Oncology

SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and...

2022-03-28 08:00 4119

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

SHANGHAI, March 25, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG (generic name: serplulimab injection) has been approved by the National Medical Products Administration (NMPA)for the treatment of adult ...

2022-03-25 21:24 4927

Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets

The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices NEW YORK, Ma...

2022-03-24 21:00 2958

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

Huma acquires AstraZeneca's digital health platform AMAZE™ and AstraZeneca becomes a shareholder of Huma LONDON and NEW YORK, March 23, 2022 /PRNewswire/ -- Huma Therapeutics Limited , a global digital health technology company advancing digital-first care delivery and res...

2022-03-24 07:00 2568

Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA

HELSINKI, Finland, March 23, 2022 /PRNewswire/ --  Inside information Nanoform Finland Plc March 22, 2022 23:45 Finnish time / 22:45 Swedish time Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in theUSA NOT FOR RELEASE, PUBLICATION OR D...

2022-03-23 08:47 1514

Servatus launches Australia's first human study into the effects of live biotherapeutics on insomnia

* Study to look at the link between the gut microbiome and sleep, by treating patients who suffer from insomnia with live biotherapeutics * Phase I/II trial will run during 2022, with results expected in 2023 * Close to 15% of the Australian population suffer from insomnia, with sleep disord...

2022-03-23 05:00 2060

CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia

TIANJIN, China, March 22, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™) has been approved by the Ministry of Health Malaysia ("MO...

2022-03-22 21:32 2015

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

SUZHOU, China, March 22, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has establis...

2022-03-22 08:19 1948

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HPV Vaccine Candidates Focus on In-house Research and Development of Novel Vaccines TAIZHOU, China, March 21, 2022 /PRNewswire/ -- The China-based novel vaccines company -Jiangsu Recbio Technology Co....

2022-03-21 14:41 2671

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...

2022-03-18 22:12 5799

WH Group's Subsidiary Smithfield Foods Partners with BioCircuit Technologies to Deliver Innovative Nerve Repair Solution

HONG KONG, March 18, 2022 /PRNewswire/ -- WH Group Limited ("WH Group" or "the Company", HKEX stock code: 288) today announced that Smithfield BioScience, a unit of WH Group's subsidiary Smithfield Foods which delivers life-saving medical solutions from porcine-derived bioproducts, and BioCircuit...

2022-03-18 16:31 2235

CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the global multi-regional ...

2022-03-18 08:37 2947
1 ... 79808182838485 ... 168